Cosmo Pharmaceuticals N.V. (CMOPF)
USD 55.0
(0.0%)
USD 55.0
(0.0%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 14.19 Million EUR | 15.64% |
| 2022 | 12.27 Million USD | -17.6% |
| 2021 | 14.89 Million USD | 113.38% |
| 2020 | 6.98 Million USD | 1.27% |
| 2019 | 6.89 Million USD | 53.21% |
| 2018 | 4.5 Million EUR | 15.64% |
| 2017 | 3.89 Million EUR | 60.15% |
| 2016 | 2.43 Million EUR | -0.44% |
| 2015 | 2.44 Million EUR | -26.61% |
| 2014 | 3.32 Million EUR | 16.33% |
| 2013 | 2.85 Million EUR | 30.43% |
| 2012 | 2.19 Million EUR | 19.26% |
| 2011 | 1.83 Million EUR | 41.49% |
| 2010 | 1.29 Million EUR | -14.26% |
| 2009 | 1.51 Million EUR | 0.53% |
| 2008 | 1.5 Million EUR | -2.71% |
| 2007 | 1.54 Million EUR | 60.35% |
| 2006 | 966 Thousand EUR | -26.03% |
| 2005 | 1.3 Million EUR | 27.91% |
| 2004 | 1.02 Million EUR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 13.9 Million EUR | -2.08% |
| 2024 Q2 | 13.9 Million EUR | 0.0% |
| 2023 Q2 | 14.66 Million USD | 9.0% |
| 2023 FY | 14.19 Million EUR | 15.64% |
| 2023 Q1 | 13.45 Million EUR | 9.56% |
| 2023 Q3 | 14.19 Million EUR | -3.16% |
| 2023 Q4 | 14.19 Million EUR | 0.0% |
| 2022 Q4 | 12.27 Million USD | 6.78% |
| 2022 FY | 12.27 Million USD | -17.6% |
| 2022 Q1 | 16.59 Million EUR | 26.51% |
| 2022 Q2 | 15.7 Million EUR | -5.39% |
| 2022 Q3 | 11.49 Million EUR | -26.78% |
| 2021 Q1 | 11.63 Million EUR | 103.88% |
| 2021 FY | 14.89 Million USD | 113.38% |
| 2021 Q2 | 9.92 Million EUR | -14.7% |
| 2021 Q3 | 15.19 Million EUR | 53.09% |
| 2021 Q4 | 13.11 Million EUR | -13.66% |
| 2020 Q4 | 5.7 Million EUR | -14.72% |
| 2020 FY | 6.98 Million USD | 1.27% |
| 2020 Q2 | 6.77 Million EUR | -9.26% |
| 2020 Q3 | 6.69 Million EUR | -1.21% |
| 2020 Q1 | 7.46 Million EUR | 21.53% |
| 2019 Q3 | 6.69 Million EUR | -3.85% |
| 2019 FY | 6.89 Million USD | 53.21% |
| 2019 Q1 | 7.81 Million EUR | 98.41% |
| 2019 Q2 | 6.96 Million EUR | -10.85% |
| 2019 Q4 | 6.14 Million EUR | -8.26% |
| 2018 FY | 4.5 Million EUR | 15.64% |
| 2018 Q3 | 4.57 Million EUR | 15.8% |
| 2018 Q2 | 3.94 Million EUR | -18.82% |
| 2018 Q1 | 4.86 Million EUR | 50.02% |
| 2018 Q4 | 3.93 Million EUR | -13.86% |
| 2017 Q4 | 3.24 Million EUR | -15.39% |
| 2017 Q2 | 2.97 Million EUR | -6.27% |
| 2017 Q1 | 3.16 Million EUR | 37.53% |
| 2017 FY | 3.89 Million EUR | 60.15% |
| 2017 Q3 | 3.83 Million EUR | 28.97% |
| 2016 Q4 | 2.3 Million EUR | -10.97% |
| 2016 Q2 | 2.99 Million EUR | -12.19% |
| 2016 Q1 | 3.41 Million EUR | 51.8% |
| 2016 FY | 2.43 Million EUR | -0.44% |
| 2016 Q3 | 2.58 Million EUR | -13.59% |
| 2015 Q2 | 3.51 Million EUR | -6.91% |
| 2015 FY | 2.44 Million EUR | -26.61% |
| 2015 Q4 | 2.24 Million EUR | -10.39% |
| 2015 Q3 | 2.5 Million EUR | -28.68% |
| 2015 Q1 | 3.77 Million EUR | 13.57% |
| 2014 FY | 3.32 Million EUR | 16.33% |
| 2014 Q4 | 3.32 Million EUR | -20.76% |
| 2014 Q3 | 4.19 Million EUR | -7.72% |
| 2014 Q2 | 4.54 Million EUR | -27.42% |
| 2014 Q1 | 6.26 Million EUR | 119.24% |
| 2013 Q3 | 3.86 Million EUR | 14.65% |
| 2013 FY | 2.85 Million EUR | 30.43% |
| 2013 Q4 | 2.85 Million EUR | -26.11% |
| 2013 Q2 | 3.37 Million EUR | -21.95% |
| 2013 Q1 | 4.32 Million EUR | 97.28% |
| 2012 Q4 | 2.19 Million EUR | 0.0% |
| 2012 Q2 | 2.78 Million EUR | 0.0% |
| 2012 FY | 2.19 Million EUR | 19.26% |
| 2011 Q2 | 2.24 Million EUR | 0.0% |
| 2011 FY | 1.83 Million EUR | 41.49% |
| 2011 Q4 | 1.83 Million EUR | 0.0% |
| 2010 Q2 | 2.25 Million EUR | 0.0% |
| 2010 Q4 | 1.29 Million EUR | 0.0% |
| 2010 FY | 1.29 Million EUR | -14.26% |
| 2009 FY | 1.51 Million EUR | 0.53% |
| 2009 Q4 | 1.51 Million EUR | 0.0% |
| 2008 FY | 1.5 Million EUR | -2.71% |
| 2007 FY | 1.54 Million EUR | 60.35% |
| 2006 FY | 966 Thousand EUR | -26.03% |
| 2005 FY | 1.3 Million EUR | 27.91% |
| 2004 FY | 1.02 Million EUR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| AstraZeneca PLC | 5.41 Billion USD | 99.738% |
| Bristol-Myers Squibb Company PFD CONV 2 | 2.66 Billion USD | 99.467% |
| CSPC Pharmaceutical Group Limited | 442.43 Million USD | 96.791% |
| Clarus Therapeutics Holdings, Inc. | 14.21 Million USD | 0.113% |
| Novartis AG | 5.91 Billion USD | 99.76% |
| PT Kalbe Farma Tbk. | 451.27 Million USD | 96.854% |